Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
User fees to go down next year
You may also be interested in...
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
Cleaning And Sterilization Needs Require Closer Attention By Reusable Device Makers – FDA
With the increasing mechanical complexity of devices that are intended to be reused by hospitals, the challenge is getting steeper for manufacturers to design the products and provide appropriate instructions to allow proper cleaning and sterilization, an FDA official stressed at a recent meeting.